Neuroprotective effects of vasoactive intestinal peptide against rat cerebral ischemia.
- Author:
Jie YANG
1
;
Zhao-hua ZHAO
;
Yi-hua QIAN
;
Xiao-dan HU
;
Ming LI
;
Chang-hong ZONG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Brain Ischemia; drug therapy; Cerebral Infarction; prevention & control; Nerve Growth Factors; blood; Neuroprotective Agents; pharmacology; Rats; Rats, Sprague-Dawley; S100 Calcium Binding Protein beta Subunit; S100 Proteins; blood; Vasoactive Intestinal Peptide; pharmacology
- From: Journal of Southern Medical University 2007;27(12):1801-1804
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the neuroprotective effect of vasoactive intestinal peptide (VIP) in rat ischemic brain injury.
METHODSVIP was administered via intracerebroventricular injection in SD rats prior to focal cerebral ischemia by intraluminal occlusion of the middle cerebral artery. The infarct volume was assessed with TTC staining, and immunohistochemistry was performed to analyze the S100beta expression in the cerebral tissue, with the serum concentrations of S100beta detected by double-antibody sandwich enzyme-linked immunosorbent assay.
RESULTSAfter VIP injection, the relative infarct volume in the rats with cerebral ischemia was significantly reduced by 32.3% as compared with the volume in the control group on day 1 (P<0.05), and the number of S100beta-positive cells was significantly decreased in the cerebral tissue (P<0.05). The injection also resulted in significantly decreased serum S100beta concentrations in the rats (P<0.05).
CONCLUSIONVIP injection can reduce the infarct volume in rats with focal cerebral ischemia, suggesting the neuroprotective effect of VIP in brain ischemia possibly by reducing S100beta overexpression.
